Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine: Pancreatic Neoplasms trials

The registry lists 10 Pancreatic Neoplasms studies with Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine as lead sponsor. 8 are open to participants now and 0 have results posted.

Early Phase 1 2Phase 1 1Phase 2 2Phase 4 1No phase 4(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Study on the Construction and Application of a Large Model Corpus for Pancreatic Cancer Based on Real Clinical CasesNot yet recruitingNCT07713823
• A Prospective Non-randomized Controlled Interventional Study on the Effect of Shouhui Tongbian Capsules Combined With Pancreatin Enteric-coated Capsules on Pancreatic Exocrine Function in Patients After Curative Resection for Pancreatic CancerNot yet recruitingNCT07557394Phase 4
• PGHD-AI Intelligent Model for the Nutritional Assessment and Intervention of Patients After Radical Surgery for Pancreatic Cancer.RecruitingNCT07167264Not applicable
• A Clinical Study Evaluating the Safety, Tolerability, and Preliminary Efficacy of Allogeneic iNKT Cell Infusion in Subjects With Advanced Pancreatic CancerNot yet recruitingNCT07055568Not applicable
• TP53 R248Q TCR-T Cell Therapy for Advanced Solid TumorNot yet recruitingNCT06619886Early Phase 1
• Cadonilimab Combined With S-1 or Capecitabine as Second-line Treatment for Advanced Pancreatic CancerRecruitingNCT06532617Phase 2
• Clinical Study of Multimodal Ablation Remodeling Immunosensitized PD-1 in the Treatment of Pancreatic Cancer With Liver MetastasisRecruitingNCT06307080Not applicable
• Utidelone Injection Combined With Gemcitabine in First-line Chemotherapy for Unresectable Advanced Pancreatic CancerRecruitingNCT05795920Phase 2
• Immunotherapy of CD8+NKG2D+ AKT Cell With Chemotherapy to Pancreatic CancerStatus unknownNCT02929797Early Phase 1
• K-001 Treatment of Advanced Pancreatic Cancer: Clinical Trial of Monotherapy's TolerabilityCompletedNCT02720666Phase 1